EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Matrix-Bound Nanovesicles as Tissue-Specific Signaling Hubs for Immunomodulation and Precision Regenerative Medicine

Peyton M Leyendecker iD, George S Hussey

Pharmaceutics · 14.07.2026 · 18 (7) · 857

DOI: 10.3390/pharmaceutics18070857 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 14.07.2026. Verfasst von Peyton M Leyendecker und 1 weiteren Autor:innen. Beteiligte Einrichtung: McGowan Institute for Regenerative Medicine, Pittsburgh, PA 15219, USA. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of regenerative medicine has repositioned the extracellular matrix (ECM) from a passive structural scaffold to a dynamic signaling hub that dictates host immunity and tissue remodeling. A critical driver of this bioactivity is the matrix-bound nanovesicle (MBV), a distinct subclass of extracellular vesicles (EVs) physically embedded within collagen fibers. Unlike fluid-phase EVs, MBVs exhibit unique release kinetics triggered by matrix degradation and possess tissue-specific molecular signatures that dictate their therapeutic potential. This review evaluates the biogenesis, isolation, and cellular tropism of MBVs, highlighting the macrophage as a central mediator of their immunomodulatory effects. We propose a “precision medicine” framework for matching MBV tissue sources—ranging from pro-angiogenic small intestinal submucosa to anti-angiogenic cartilage—to the specific pathological requirements of the target injury. Furthermore, we discuss post-harvest engineering strategies, including surface functionalization via click chemistry and exogenous cargo loading, to enhance MBV targeting and potency. Finally, we address the translational hurdles of protocol standardization and pharmacokinetic characterization required to transition MBVs into a scalable, cell-free platform for regenerative therapy.

Schlagwörter

Stichwörter der Autor:innen

cargo loadingextracellular matrix (ECM)extracellular vesicles (EVs)interleukin-33 (IL-33)macrophage polarizationmatrix-bound nanovesicles (MBVs)precision medicineregenerative medicinesurface engineeringtissue-specific bioactivity

Autor:innen und Institutionen

  • McGowan Institute for Regenerative Medicine, Pittsburgh, PA 15219, USA.
  • Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
  • Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
  • Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA.

ORCID-Profile: Peyton M Leyendecker

Zitieren

APA

Leyendecker, P. M., & Hussey, G. S. (2026). Matrix-Bound Nanovesicles as Tissue-Specific Signaling Hubs for Immunomodulation and Precision Regenerative Medicine. Pharmaceutics, 18(7), 857. https://doi.org/10.3390/pharmaceutics18070857

Vancouver

Leyendecker PM, Hussey GS. Matrix-Bound Nanovesicles as Tissue-Specific Signaling Hubs for Immunomodulation and Precision Regenerative Medicine. Pharmaceutics. 2026;18(7):857. doi:10.3390/pharmaceutics18070857

BibTeX
@article{Leyendecker2026,
  author = {Leyendecker, Peyton M and Hussey, George S},
  title = {Matrix-Bound Nanovesicles as Tissue-Specific Signaling Hubs for Immunomodulation and Precision Regenerative Medicine},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {857},
  doi = {10.3390/pharmaceutics18070857}
}
Kostenlos starten →